Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome
Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome
复制标题
DOI：
10.1002/ejhf.148
复制
发表时间：
2014-10-01
影响因子：
18.2
通讯作者：
Schultheiss, Heinz-Peter
中科院分区：
文献类型：
--
作者：
Escher, Felicitas;Kuehl, Uwe;Schultheiss, Heinz-Peter
心肌内炎症被认为是炎症性心肌病（CMi）的一个不良预后因素。然而，与长期病程预测相关的免疫系统因素的确切性质仍然难以捉摸。本研究的目的是分析穿孔素在一个大的队列患者CMi.Methods和resultsWe的预后相关性进行了调查，495例连续疑似CMi患者，进行肌内膜活检（EMB），并检查血流动力学测量后，一个长的随访期（四分位数范围10.2- 37.1个月）。在EMB中，通过组织学和免疫组织学评估心肌炎症。随访时，388例患者（I组）显示稳定的轻度功能障碍或显著改善，LVEF从46.2 ± 14.8%上升至64.3 ± 12.3%（P
AimsIntramyocardial inflammation is considered an adverse prognostic factor in inflammatory cardiomyopathy (CMi). However, the precise nature of immune system factors relevant for the prediction of long-term course remains elusive. The aim of this study was to analyse the prognostic relevance of perforin in a large cohort of patients with CMi.Methods and resultsWe investigated 495 consecutive patients with suspected CMi, undergoing endomyocardial biopsies (EMBs), and examined haemodynamic measurements after a long follow-up period (interquartile range 10.2-37.1months). In EMBs, myocardial inflammation was assessed by histology and immunohistology. At follow-up, 388 patients (Group I) showed stable mild dysfunction or significant improvement, with LVEF rising from 46.214.8% to 64.3 +/- 12.3% (P